

EXHIBIT A

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS FOR COLLEEN MCGINN					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
12/14/2018	Teva Affirm	11	1	11	20
12/14/2018	Teva Affirm	13	17	14	2
12/14/2018	Teva Affirm	27	9	28	14
12/14/2018	Teva Affirm	29	4	29	16
12/14/2018	Teva Affirm	31	15	32	4
12/14/2018	Teva Affirm	31	17	32	4
12/14/2018	Teva Affirm	31	17	32	4
12/14/2018	Teva Affirm	34	10	35	7
12/14/2018	Teva Affirm	96	24	97	21
12/14/2018	Teva Affirm	129	5	130	21

PLAINTIFFS' OBJECTIONS AND TEVA'S RESPONSES FOR COLLEEN MCGINN

DEPO DATE	NOTES				
	Begin Page at	Begin Line at	End Page at	End Line at	NOTES
12/14/2018	129	5	130	21	Plaintiffs' Objection: Non-responsive; speculation; lacks foundation
12/14/2018	129	5	130	21	Response: Responsive because witness explains that duties and responsibilities under DEA regulations exist, but are subject to shifting interpretations. Answer is not speculative and has foundation because answer reflects personal knowledge and experience of the witness. Foundation regarding knowledge and experience in preceeding testimony.

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR DAVID MYERS					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
12/13/2018	Teva Affirm	9	1	11	2
12/13/2018	Allergan & MNK Affirm	10	1	11	2
12/13/2018	Teva Affirm	24	15	26	14
12/13/2018	Allergan & MNK Affirm	29	23	30	10
12/13/2018	Teva Affirm	29	23	32	23
12/13/2018	Allergan & MNK Affirm	30	22	32	23
12/13/2018	Teva Affirm	34	5	35	1
12/13/2018	Allergan & MNK Affirm	34	5	35	1
12/13/2018	Teva Affirm	35	4	35	16
12/13/2018	Allergan & MNK Affirm	35	4	35	16
12/13/2018	Teva Affirm	36	9	37	2
12/13/2018	Allergan & MNK Affirm	36	9	37	2
12/13/2018	Teva Affirm	37	17	40	14
12/13/2018	Allergan & MNK Affirm	37	17	40	14
12/13/2018	Teva Affirm	40	22	41	3
12/13/2018	Allergan & MNK Affirm	40	22	41	3
12/13/2018	Teva Affirm	41	12	41	24
12/13/2018	Allergan & MNK Affirm	41	12	41	24
12/13/2018	Allergan & MNK Affirm	42	2	42	7
12/13/2018	Teva Affirm	42	2	42	12
12/13/2018	Teva Affirm	42	14	42	18
12/13/2018	Teva Affirm	43	4	43	6
12/13/2018	Teva Affirm	43	9	43	9
12/13/2018	Allergan & MNK Affirm	43	10	45	16
12/13/2018	Teva Affirm	43	11	45	16
12/13/2018	Teva Affirm	45	18	46	13
12/13/2018	Allergan & MNK Affirm	45	18	46	13
12/13/2018	Allergan & MNK Affirm	47	14	47	19
12/13/2018	Teva Affirm	47	14	49	14
12/13/2018	Allergan & MNK Affirm	49	7	49	14

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR DAVID MYERS					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
12/13/2018	Allergan & MNK Affirm	49	16	49	21
12/13/2018	Teva Affirm	49	16	53	11
12/13/2018	Allergan & MNK Affirm	50	5	52	4
12/13/2018	Allergan & MNK Affirm	52	8	53	11
12/13/2018	Allergan & MNK Affirm	53	13	53	14
12/13/2018	Teva Affirm	53	13	54	9
12/13/2018	Allergan & MNK Affirm	53	22	54	9
12/13/2018	Allergan & MNK Affirm	59	17	60	7
12/13/2018	Teva Affirm	59	17	62	17
12/13/2018	Allergan & MNK Affirm	61	6	61	12
12/13/2018	Plaintiff Counter	62	18	63	14
12/13/2018	Teva Affirm	81	5	82	13
12/13/2018	Allergan & MNK Affirm	81	5	82	13
12/13/2018	Teva Affirm	82	15	83	21
12/13/2018	Allergan & MNK Affirm	82	15	83	21
12/13/2018	Allergan & MNK Affirm	86	1	86	9
12/13/2018	Teva Affirm	103	6	103	13
12/13/2018	Teva Affirm	103	15	104	8
12/13/2018	Teva Affirm	104	10	104	13
12/13/2018	Teva Affirm	104	20	104	24
12/13/2018	Teva Affirm	105	2	105	10
12/13/2018	Teva Affirm	105	13	105	18
12/13/2018	Allergan & MNK Affirm	114	14	114	18
12/13/2018	Teva Affirm	114	15	114	18
12/13/2018	Teva Affirm	114	21	115	2
12/13/2018	Allergan & MNK Affirm	114	21	115	2
12/13/2018	Teva Affirm	115	6	115	10
12/13/2018	Allergan & MNK Affirm	115	6	115	10
12/13/2018	Teva Affirm	115	14	115	19
12/13/2018	Allergan & MNK Affirm	115	14	115	19

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR DAVID MYERS					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
12/13/2018	Allergan & MNK Affirm	184	21	184	24
12/13/2018	Allergan & MNK Affirm	185	3	185	9
12/13/2018	Allergan & MNK Affirm	185	11	185	12
12/13/2018	Plaintiff Counter	185	14	185	22
12/13/2018	Allergan & MNK Affirm	185	23	186	1
12/13/2018	Allergan & MNK Affirm	186	3	186	4
12/13/2018	Teva Affirm	361	12	361	18
12/13/2018	Teva Affirm	362	1	362	4
12/13/2018	Teva Affirm	362	6	363	5
12/13/2018	Teva Affirm	363	7	363	17
12/13/2018	Teva Affirm	364	3	364	13
12/13/2018	Teva Affirm	364	17	364	24
12/13/2018	Allergan & MNK Affirm	366	14	367	1
12/13/2018	Teva Affirm	366	14	367	8
12/13/2018	Teva Affirm	367	11	367	22
12/13/2018	Teva Affirm	368	1	368	2
12/13/2018	Plaintiff Counter	368	4	368	7
12/13/2018	Plaintiff Counter	368	9	368	9
12/13/2018	Teva Affirm	368	20	368	22
12/13/2018	Teva Affirm	369	1	369	11
12/13/2018	Teva Affirm	369	13	369	13
12/13/2018	Allergan & MNK Affirm	369	20	371	4
12/13/2018	Teva Affirm	369	21	371	4
12/13/2018	Allergan & MNK Affirm	371	6	371	11
12/13/2018	Teva Affirm	371	6	371	15
12/13/2018	Teva Affirm	371	18	372	3
12/13/2018	Teva Affirm	372	6	372	13
12/13/2018	Teva Affirm	372	16	372	24
12/13/2018	Teva Affirm	373	2	373	5
12/13/2018	Teva Affirm	373	16	373	17
12/13/2018	Teva Affirm	373	19	375	4
12/13/2018	Allergan & MNK Affirm	379	24	380	5

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR DAVID MYERS					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
12/13/2018	Allergan & MNK Affirm	380	7	380	13
12/13/2018	Allergan & MNK Affirm	383	16	383	19
12/13/2018	Allergan & MNK Affirm	383	21	384	11
12/13/2018	Allergan & MNK Affirm	384	14	385	24
12/13/2018	Allergan & MNK Affirm	386	4	386	9

PLAINTIFFS' OBJECTIONS AND TEVA'S RESPONSES FOR DAVID MYERS					
DEPO DATE	NOTES				
	Begin Page at	Begin Line at	End Page at	End Line at	NOTES
12/13/2018	103	6	105	18	Plaintiffs' Objection: relevance
12/13/2018	103	6	105	18	Response: Relevant to understanding corporate ownership and responsibility for Anda entity and related distribution of opioid products.
12/13/2018	114	21	115	19	Plaintiffs' Objection: relevance
12/13/2018	114	21	115	19	Response: Relevant to differentiating advertising between brand and generic products.
12/13/2018	183	21	186	4	Plaintiffs' Objection: argumentative
12/13/2018	183	21	186	4	Response: Objection does not correspond with designated testimony. The examination is not argumentative in that the questions seek, and the responses provide, factual testimony.
12/13/2018	185	14	185	22	Objection to Plaintiffs' Counter: Improper Counter Designation. Counter is mere attempt by Plaintiffs to designate testimony which should have been affirmatively designated.
12/13/2018	368	4	368	9	Objection to Plaintiffs' Counter: VG; HYP; 602

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR THOMAS NAPOLI					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
1/17/2019	Teva Affirm	8	1	9	22
1/17/2019	Allergan & MNK Affirm	8	1	9	22
1/17/2019	Teva Affirm	10	8	11	15
1/17/2019	Allergan & MNK Affirm	10	8	11	15
1/17/2019	Plaintiff Counter	11	16	11	19
1/17/2019	Teva Affirm	11	20	12	8
1/17/2019	Allergan & MNK Affirm	11	20	12	8
1/17/2019	Teva Affirm	12	22	14	6
1/17/2019	Teva Affirm	12	22	14	6
1/17/2019	Allergan & MNK Affirm	12	22	14	6
1/17/2019	Teva Affirm	14	16	15	1
1/17/2019	Allergan & MNK Affirm	14	16	15	1
1/17/2019	Teva Affirm	17	3	18	5
1/17/2019	Allergan & MNK Affirm	17	3	18	5
1/17/2019	Teva Affirm	18	17	19	2
1/17/2019	Allergan & MNK Affirm	18	17	19	2
1/17/2019	Teva Affirm	20	17	22	1
1/17/2019	Allergan & MNK Affirm	20	17	22	1
1/17/2019	Teva Affirm	22	6	23	8
1/17/2019	Allergan & MNK Affirm	22	6	23	8
1/17/2019	Allergan & MNK Affirm	24	13	27	23
1/17/2019	Teva Affirm	30	13	32	21
1/17/2019	Allergan & MNK Affirm	30	13	32	21
1/17/2019	Allergan & MNK Affirm	36	3	37	16
1/17/2019	Plaintiff Counter	40	6	41	3
1/17/2019	Allergan & MNK Affirm	41	4	41	24
1/17/2019	Teva Affirm	41	18	43	3
1/17/2019	Allergan & MNK Affirm	42	1	43	3
1/17/2019	Teva Affirm	59	11	61	7

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR THOMAS NAPOLI					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
1/17/2019	Allergan & MNK Affirm	59	11	61	7
1/17/2019	Teva Affirm	61	23	62	13
1/17/2019	Teva Affirm	73	4	75	6
1/17/2019	Allergan & MNK Affirm	73	4	75	6
1/17/2019	Teva Affirm	88	2	89	5
1/17/2019	Allergan & MNK Affirm	88	2	89	5
1/17/2019	Teva Affirm	96	11	97	21
1/17/2019	Allergan & MNK Affirm	96	11	97	21
1/17/2019	Teva Affirm	100	3	101	3
1/17/2019	Allergan & MNK Affirm	100	3	101	3
1/17/2019	Teva Affirm	106	15	107	17
1/17/2019	Allergan & MNK Affirm	106	15	107	17
1/17/2019	Plaintiff Counter	113	21	118	7
1/17/2019	Teva Affirm	117	16	117	18
1/17/2019	Allergan & MNK Affirm	117	16	117	18
1/17/2019	Teva Affirm	118	8	118	17
1/17/2019	Allergan & MNK Affirm	118	8	118	17
1/17/2019	Teva Affirm	121	2	121	8
1/17/2019	Allergan & MNK Affirm	121	2	121	8
1/17/2019	Teva Affirm	121	12	123	10
1/17/2019	Allergan & MNK Affirm	121	12	123	10
1/17/2019	Teva Affirm	133	6	134	23
1/17/2019	Allergan & MNK Affirm	133	6	134	23
1/17/2019	Teva Affirm	136	10	137	16
1/17/2019	Allergan & MNK Affirm	136	10	137	16
1/17/2019	Allergan & MNK Affirm	155	22	156	2
1/17/2019	Teva Affirm	155	22	156	22
1/17/2019	Allergan & MNK Affirm	156	5	157	3
1/17/2019	Teva Affirm	157	16	158	23

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR THOMAS NAPOLI					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
1/17/2019	Allergan & MNK Affirm	158	5	158	9
1/17/2019	Allergan & MNK Affirm	158	11	159	5
1/17/2019	Allergan & MNK Affirm	159	7	159	15
1/17/2019	Allergan & MNK Affirm	162	14	162	17
1/17/2019	Allergan & MNK Affirm	162	21	163	5
1/17/2019	Allergan & MNK Affirm	163	8	164	4
1/17/2019	Allergan & MNK Affirm	164	8	164	11
1/17/2019	Allergan & MNK Affirm	165	17	166	23
1/17/2019	Plaintiff Counter	165	24	168	18
1/17/2019	Teva Affirm	166	1	166	23
1/17/2019	Teva Affirm	168	19	170	12
1/17/2019	Allergan & MNK Affirm	168	19	170	12
1/17/2019	Teva Affirm	172	12	173	24
1/17/2019	Allergan & MNK Affirm	172	12	173	24
1/17/2019	Allergan & MNK Affirm	185	11	186	13
1/17/2019	Allergan & MNK Affirm	189	11	193	2
1/17/2019	Allergan & MNK Affirm	193	4	193	16
1/17/2019	Plaintiff Counter	193	18	195	9
1/17/2019	Allergan & MNK Affirm	195	10	195	14
1/17/2019	Plaintiff Counter	195	15	196	7
1/17/2019	Plaintiff Counter	196	20	197	18
1/17/2019	Plaintiff Counter	197	21	198	24
1/17/2019	Plaintiff Counter	199	3	199	17
1/17/2019	Plaintiff Counter	200	6	202	15
1/17/2019	Plaintiff Counter	202	18	203	18

DEFENDANTS' AFFIRMATIVE DEPOSITION DESIGNATIONS AND PLAINTIFFS' COUNTERS FOR THOMAS NAPOLI					
DEPO DATE	DESIGNATION TYPE	DEFENDANTS' AFFIRMATIVE DESIGNATIONS			
		Begin Page at	Begin Line at	End Page at	End Line at
1/17/2019	Teva Affirm	217	13	218	14
1/17/2019	Plaintiff Counter	218	15	223	21
1/17/2019	Teva Affirm	223	22	224	14
1/17/2019	Allergan & MNK Affirm	255	14	256	21
1/17/2019	Teva Affirm	257	8	261	19
1/17/2019	Allergan & MNK Affirm	257	8	261	19
1/17/2019	Allergan & MNK Affirm	262	17	263	9
1/17/2019	Allergan & MNK Affirm	264	1	273	10
1/17/2019	Allergan & MNK Affirm	273	12	273	17
1/17/2019	Allergan & MNK Affirm	276	10	281	19
1/17/2019	Allergan & MNK Affirm	293	10	297	21
1/17/2019	Allergan & MNK Affirm	297	23	298	22
1/17/2019	Allergan & MNK Affirm	299	1	300	4
1/17/2019	Allergan & MNK Affirm	314	3	319	5
1/17/2019	Allergan & MNK Affirm	319	17	323	12
1/17/2019	Teva Affirm	338	19	340	7
1/17/2019	Allergan & MNK Affirm	338	19	343	17
1/17/2019	Teva Affirm	341	6	343	15

PLAINTIFFS' OBJECTIONS AND TEVA'S RESPONSES FOR THOMAS NAPOLI					
DEPO DATE	NOTES				
	Begin Page at	Begin Line at	End Page at	End Line at	NOTES
1/17/2019	88	2	89	5	Plaintiffs' Objection: relevance
1/17/2019	88	2	89	5	Response: Relevant to explaining processes for suspicious order monitoring, which is directly relevant to plaintiffs' claims against
1/17/2019	113	21	118	7	Objection to Plaintiffs' Counter: Improper Counter Designation. Counter is mere attempt by Plaintiffs to designate testimony which should have been affirmatively designated; 602
1/17/2019	193	19	195	9	Objection to Plaintiffs' Counter: 602
1/17/2019	196	20	197	18	Objection to Plaintiffs' Counter: Improper Counter Designation. Counter is mere attempt by Plaintiffs to designate testimony which should have been affirmatively designated; 602
1/17/2019	197	21	198	24	Objection to Plaintiffs' Counter: Improper Counter Designation. Counter is mere attempt by Plaintiffs to designate testimony which should have been affirmatively designated; 602
1/17/2019	199	3	199	17	Objection to Plaintiffs' Counter: Improper Counter Designation. Counter is mere attempt by Plaintiffs to designate testimony which should have been affirmatively designated; 602
1/17/2019	200	6	202	15	Objection to Plaintiffs' Counter: Improper Counter Designation. Counter is mere attempt by Plaintiffs to designate testimony which should have been affirmatively designated; 602
1/17/2019	202	18	203	18	Objection to Plaintiffs' Counter: Improper Counter Designation. Counter is mere attempt by Plaintiffs to designate testimony which should have been affirmatively designated; 602
1/17/2019	218	15	223	21	Objection to Plaintiffs' Counter: Overbroad
1/17/2019	338	19	341	4	Plaintiffs' Objection: foundation; relevance
1/17/2019	338	19	341	4	Reponse: Relevant to suspicious order monitoring, internal controls protocols, and DEA compliance. Foundation regarding reporting set forth in prior testimony and based upon personal experience of witness.
1/17/2019	341	5	343	17	Plaintiffs' Objection: relevance
1/17/2019	341	5	343	17	Response: Relevant to company and witness's views on suspicious order monitoring and internal controls.